Specialty chemical manufacturer Polysciences Inc. has introduced a new line bioprocessing offerings called Kyfora Bio, according to a Jan. 2 news release.
The company’s Kyfora Bio operations will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The company will house its Kyfora Bio operations in a 45,000-square-foot cGMP facility outfitted with administrative offices, research and development (R&D) labs, manufacturing suites, and quality control labs for chemical and biological performance testing.
The new site is located near Polysciences' 250,000-square-foot Warrington, Pennsylvania, campus, which serves as the company's headquarters. The new bioprocessing line falls in line with the company’s plan to be a “partner of choice in supplying key cGMP compliant materials to the cell and gene therapy market,” says Scott Knorr, president, Kyfora Bio.
